LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.
Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|Brain Tumor
BIOLOGICAL: lerapolturev|BIOLOGICAL: pembrolizumab
Objective Response Rate (ORR), Objective response rate (comprised of patients meeting an objective radiographic response or ORR): Patients achieving a complete response (CR) or partial response (PR)., 24 months|Frequency and Severity of Treatment-emergent Adverse Events, Count of participants experiencing a treatment-emergent adverse event is reported here. Detailed frequency and severity data are reported in the Adverse Event table., Up to 30 days after discontinuation of pembrolizumab|Duration of Response (DOR), DOR: Time from first ORR observed (once confirmed) until PD first observed (once confirmed) or death; whichever comes first., 24 months|Durable Radiographic Response (DRR), DRR: An ORR that persists for â‰¥ 6 months., 24 months
Disease Control Rate (DCR), Proportion of patients achieving stable disease (SD), CR or PR via protocol-specified response criteria, 24 months|Survival Assessed by Kaplan-Meier Methods, Overall survival (months) post-lerapolturev infusion estimated by Kaplan-Meier methods., 24 months
This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.